Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "Rs-1"

256 News Found

Govt increased expenditure on health during 2013 - 18 : Report
Public Health | November 29, 2021

Govt increased expenditure on health during 2013 - 18 : Report

Share of government health expenditure in total health expenditure increases to 40.8% (2017-18) from 28.6% (2013-14)


Air pollution reduces life expectancy by eight years in India
News | November 25, 2021

Air pollution reduces life expectancy by eight years in India

India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution


Ipca Laboratories acquires 26 % stake in Lyka Labs, makes open offer
News | November 24, 2021

Ipca Laboratories acquires 26 % stake in Lyka Labs, makes open offer

For the six months ended September 30, 2021, Lyka had reported revenues of Rs 109.87 crore


J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22
News | November 12, 2021

J.B Chemicals & Pharmaceuticals PAT at Rs 98 cr. in Q2FY22

J. B. Chemicals & Pharmaceuticals Limited (JBCPL), announced its financial results for the second quarter ended 30th September, 2021


Wockhardt PAT at Rs 33.53 cr. in Q2FY22
News | November 09, 2021

Wockhardt PAT at Rs 33.53 cr. in Q2FY22

The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.


Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22
News | November 09, 2021

Aurobindo Pharma PAT drops to Rs 696.99 cr in Q2FY22

The Board of Directors of Aurobindo Pharma have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Caplin Point Labs posts  Q2FY22 PAT at Rs 74.98 Cr
News | November 02, 2021

Caplin Point Labs posts Q2FY22 PAT at Rs 74.98 Cr

The Board of Directors of Caplin Point Laboratories at its meeting have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021


Lyka Labs  Q2FY22 consolidated PAT at Rs. 28.43Cr
News | November 01, 2021

Lyka Labs Q2FY22 consolidated PAT at Rs. 28.43Cr

Lyka Labs has reported consolidated financial results for the period ended September 30, 2021


Sanofi India PAT at Rs. 529.8 cr in Q3CY21
News | October 27, 2021

Sanofi India PAT at Rs. 529.8 cr in Q3CY21

The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021


NPPA fixes ceiling price for anti-diabetic generic medicines
Policy | October 26, 2021

NPPA fixes ceiling price for anti-diabetic generic medicines

A total of 12 generic medicines have been included in the list